Rhinitis/rhinorrhea (intranasal products):
Indications for: RYALTRIS
Seasonal allergic rhinitis.
Use 2 sprays in each nostril twice daily.
<12yrs: not established.
Risk of epistaxis, nasal ulcerations, nasal septal perforations, impaired nasal wound healing, local Candida infections; monitor periodically. Recent nasal septal ulcers, nasal surgery, or nasal trauma: avoid until healing has occurred. Discontinue if Candida infections or hypersensitivity reactions occur. Monitor closely if change in vision or those with a history of increased intraocular pressure, glaucoma, and/or cataracts. Immunosuppression. Respiratory tract tuberculosis. Infections (eg, fungal, bacterial, viral, ocular herpes simplex). If exposed to measles or chickenpox, may need immunoglobulin or VZIG prophylactic therapy. Hypercorticism. Adrenal suppression. Monitor routinely for growth in children. Hepatic impairment. Pregnancy. Nursing mothers.
Antihistamine + corticosteroid.
Avoid concomitant alcohol or other CNS depressants. Caution with strong CYP3A4 inhibitors (eg, ketoconazole).
Dysgeusia, epistaxis, nasal discomfort; somnolence, impaired mental alertness.
Olopatadine: renal (~70%), fecal (~17%). Half-life: 9 hours (olopatadine); 18 hours (mometasone furoate).
Generic Drug Availability:
Spray—29g (240 sprays)